Prognostic and clinicopathological significance of nm23-H1 expression in non-small cell lung cancer: A meta-analysis

• Published in: Medicine (Baltimore) Vol. 101; no. 39; p. e30815
• Main Authors: Li, Dailong, Li, Wanqiang, Tian, Cheng, Pang, Yaqi, Xu, Lu, Wang, Yuke, Xu, Xinhua
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 30.09.2022
• Subjects: Biomarkers, Tumor - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Humans; Lung Neoplasms - pathology; Neoplasm Staging; NM23 Nucleoside Diphosphate Kinases - metabolism; Prognosis; Systematic Review and Meta-Analysis
• ISSN: 1536-5964; 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000030815

The relationship between the expression of nm23-H1 and the invasion and prognosis of non-small cell lung cancer (NSCLC) is still controversial. Therefore, we conducted a meta-analysis to determine the prognostic value of nm23-H1 in patients with NSCLC. And to explore the relationship between the expression of nm23-H1 and clinicopathological features in patients with NSCLC. Literature search in PubMed, EMBASE, Cochrane Library, CNKI, and WanFang database was performed up to June 14, 2021. Studies on the expression and clinical significance of nm23-H1 in NSCLC were included. According to the inclusion and exclusion criteria, 2 researchers independently screened the literatures, extracted the data, and evaluated the quality. Meta-analysis was performed using RevMan 5.4 software (Nordic Cochran Centre, Copenhagen, Denmark). Twenty-five studies met our inclusion criteria and were finally included for the analysis, involving 2198 participants. Our meta-analysis revealed that nm23-H1 expression was associated with tumor differentiation (OR = 0.54, 95% CI: 0.42-0.70, P < .00001), TNM stage (OR = 1.70, 95% CI: 1.23-2.34, P = .001), and lymph node status (OR = 0.26, 95% CI, 0.17-0.39, P < .00001), but have no associate with sex, age, pathological type, and T stages. Additionally, low nm23-H1 expression reduced the 3-year survival rate (OR = 2.74, 95% CI: 1.54-4.86, P = .0006) and 5-year survival rate (OR = 2.78, 95% CI: 1.36-5.69, P = .005). Nm23-H1 can be used as a biomarker to predict tumor invasiveness and evaluate the prognosis of patients with NSCLC.